DNAvaccine.com Presents: Vector Design for Vaccine and Gene Therapy Applications with Dr. Jim Williams from Nature Technology
Join us for a Webinar on April 24
Extensive research to improve plasmid delivery has resulted in advanced methods such as electroporation that dramatically improve gene transfer compared with naked DNA delivery. Plasmid-directed gene expression is now near the efficacy barrier that to date has prevented DNA medicine commercialization for human applications. However, most DNA vaccines and non-viral gene therapeutics currently in development utilize suboptimal vector backbones. In this webinar I will discuss DNA vaccine vector and synthetic gene insert design strategies that may be applied to create regulatory agency compliant non viral plasmid vectors with improved transgene expression and immunogenicity.
Dr. Williams is the Chief Scientific Officer and Vice President, Research and Development, at Nature Technology Corporation (NTC). Dr. Williams has 17 years biotech industry experience directing microbial fermentation, cell line, & vector design programs for protein & DNA-based vaccine or therapeutic product applications. He oversaw development of NTC’s minimal antibiotic-free plasmid vector/manufacturing platform for DNA vaccination and gene therapy applications.
DNAvaccine.com Presents: Vector design for vaccine and gene therapy applications
Tuesday, April 24, 2012
1:00 PM – 2:00 PM EDT
After registering you will receive a confirmation email containing information about joining the Webinar.
Required: Windows® 7, Vista, XP or 2003 Server
Required: Mac OS® X 10.5 or newer
Space is limited.
Reserve your Webinar seat now at: